 |
| Vigorex |
Composition: Each Vigorex tablet contains:
Sildenafil (as citrate) 50 mg
Sildenafil (as citrate) 50 mg
Mechanism of Action:
Vigorex is a selective phosphodiesterase type 5 (PDE5) inhibitor.
In response to sexual stimulation, a chemical substance (nitric oxie) is released by neurons and endothelial cells into the corpus cavernosal smooth nuscle cells, which stimulates the synthesis of cyclic guanosne monophosphate (cGMP).
(cGMP) leads to relaxation of the smooth muscle cells in the penile vesculature resulting in an increase in blood flow and erection.
Vigorex inhibits the breakdown of (cGMP) by blocking the (PDE5) so-enzyme, responsible for (cGMP) degradation and thus ncreases penile (cGMP) l?vels in response to natural sexual stimulation in erectile dysfunction patients.
Vigorex restores the natural response to sexual stimulation and does not increase the sexual desire.
The effect of Vigorex occurs only in response to sexual stimulation, it does not work in the absence of sexual stimulation. Indications: - Vigorex is indicated for the treatment f erectile dysfunctions in men, regardless
of baseline severity, etiology and age. / - Vigorex was shown to improve frequercy, hardness and maintenance of erection: - Vigorex shows a significant response with hypertensive patients, diabetics and
patients with spinal cord injury and in patients after radical prostatectomy. Contraindi’ations:
• Vigorex is contraindicated in patients with known hypersensitivity to any of the tablet ingredients.
• The main contraindication is the concomitant administration with organic Nitrates of any form including sublingual, transdermal and intravenous. • Vigorex was shown to potentiate the hypotensive effects of Nitrates, and its administration to patients who are concurrently using organic nitrates in any form, is therefore contraindicated.
Vigorex is a selective phosphodiesterase type 5 (PDE5) inhibitor.
In response to sexual stimulation, a chemical substance (nitric oxie) is released by neurons and endothelial cells into the corpus cavernosal smooth nuscle cells, which stimulates the synthesis of cyclic guanosne monophosphate (cGMP).
(cGMP) leads to relaxation of the smooth muscle cells in the penile vesculature resulting in an increase in blood flow and erection.
Vigorex inhibits the breakdown of (cGMP) by blocking the (PDE5) so-enzyme, responsible for (cGMP) degradation and thus ncreases penile (cGMP) l?vels in response to natural sexual stimulation in erectile dysfunction patients.
Vigorex restores the natural response to sexual stimulation and does not increase the sexual desire.
The effect of Vigorex occurs only in response to sexual stimulation, it does not work in the absence of sexual stimulation. Indications: - Vigorex is indicated for the treatment f erectile dysfunctions in men, regardless
of baseline severity, etiology and age. / - Vigorex was shown to improve frequercy, hardness and maintenance of erection: - Vigorex shows a significant response with hypertensive patients, diabetics and
patients with spinal cord injury and in patients after radical prostatectomy. Contraindi’ations:
• Vigorex is contraindicated in patients with known hypersensitivity to any of the tablet ingredients.
• The main contraindication is the concomitant administration with organic Nitrates of any form including sublingual, transdermal and intravenous. • Vigorex was shown to potentiate the hypotensive effects of Nitrates, and its administration to patients who are concurrently using organic nitrates in any form, is therefore contraindicated.
SIGMA Precautions: There is a potential for cardiac risk of sexual activity in patients with pre-existing cardiovascular disease. Therefore, treatments for erectile dysfunctions, including Vigorex should not be generally used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status. Vigorex has systemic vasodilatory properties that resulted in transient decrease in supine blood pressure in healthy volunteers, so before prescribing Vigorex, physicians should consider the following: - Patients who have suffered a myocardial infarction, stroke, or life-threatening arrythmia within the last 6 months.
• Patients with resting hypotension (BP below 90/50) or hypertension (BP over 170/110).
• Patients with cardiac failure or coronary artery disease causing unstable angina.
• Patients with retinitis pigmentosa (a minority of patients have genetic disorders of retinal phosphodiesterases). Adverse Reactions: The adverse events reported with Sildenafil were generally transient and mild to moderate in nature. The adverse events reported with patients taking Sildenafil, as the recommended dosage, include: - Headache, Flushing, Dyspepsia, Nausea, Congestion and Diarrhea. - Abnormal vision: Mild and transient, Predominantly colour tinge to vision but also increased sensitivity to light or blurred vision. - Other adverse reactions occured at a rate > 2% but equally common with placebo include: respiratory tract infection, urinary tract infection, back pain and arthralgia. Dosage and idministration: For most patients, the recommended dose is one tablet of 50 mg to be taken as needed approximately 1 hour before sexual activity. However Vigorex may be taken anywhere from 4 hours to 0.5 hour before sexual activity.Based on effectiveness and toleration, the dose may be increased to a maximum dose of 100 mg (2 tab.) or decreased to 25 mg (1/2 tab). Vigorex should be taken only once / day. Package:
Vigorex is supplied in a box containing one blister of 2 tablets. 0412087
• Patients with resting hypotension (BP below 90/50) or hypertension (BP over 170/110).
• Patients with cardiac failure or coronary artery disease causing unstable angina.
• Patients with retinitis pigmentosa (a minority of patients have genetic disorders of retinal phosphodiesterases). Adverse Reactions: The adverse events reported with Sildenafil were generally transient and mild to moderate in nature. The adverse events reported with patients taking Sildenafil, as the recommended dosage, include: - Headache, Flushing, Dyspepsia, Nausea, Congestion and Diarrhea. - Abnormal vision: Mild and transient, Predominantly colour tinge to vision but also increased sensitivity to light or blurred vision. - Other adverse reactions occured at a rate > 2% but equally common with placebo include: respiratory tract infection, urinary tract infection, back pain and arthralgia. Dosage and idministration: For most patients, the recommended dose is one tablet of 50 mg to be taken as needed approximately 1 hour before sexual activity. However Vigorex may be taken anywhere from 4 hours to 0.5 hour before sexual activity.Based on effectiveness and toleration, the dose may be increased to a maximum dose of 100 mg (2 tab.) or decreased to 25 mg (1/2 tab). Vigorex should be taken only once / day. Package:
Vigorex is supplied in a box containing one blister of 2 tablets. 0412087
Sildenafil
SIGMA Pharlcal Industries -Fgypt-S.A.E.
No comments:
Post a Comment